# Biotech Daily Digest ‚Äî 2026-01-08

**43 items from 5 sources**

## Summary by Source

- Eli Lilly Press Releases: 1 item
- Endpoints News: 11 items
- Fierce Biotech: 9 items
- MHRA ‚Äì News: 1 item
- arXiv q-bio: 21 items


## Eli Lilly Press Releases

- **[Lilly to acquire Ventyx Biosciences to advance oral therapies targeting inflammatory-mediated diseases](https://investor.lilly.com/news-releases/news-release-details/lilly-acquire-ventyx-biosciences-advance-oral-therapies)**  
  _Wed, 07 Jan 2026 16:17:00 -0500_  
  Ventyx's clinical pipeline includes multiple small molecules with potential for oral therapies addressing chronic inflammation Acquisition builds on Lilly's established capabilities in inflammatory-mediated diseases INDIANAPOLIS , Jan. 7, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE:¬†LLY) and


## Endpoints News

- **[Ollin‚Äôs drug clears retinal disease better than Roche‚Äôs Vabysmo in Phase 1b trial](https://endpoints.news/ollins-drug-clears-retinal-disease-better-than-roches-vabysmo-in-phase-1b-trial/)**  
  _Thu, 08 Jan 2026 13:00:44 +0000_  
  Just four months after its debut, Ollin Biosciences shared positive data from an early-stage study of its bispecific antibody for retinal diseases, and is already mapping out its registrational plans.

 Ollin‚Äôs drug, called OLN324, is ...

- **[Inside Doctronic's experiment to allow AI to refill prescriptions](https://endpoints.news/inside-doctronics-experiment-to-allow-ai-to-refill-prescriptions/)**  
  _Thu, 08 Jan 2026 13:00:33 +0000_  
  A New York startup is pushing the boundaries of using AI in clinical practice with a new program that allows the technology to refill patients‚Äô prescriptions without a doctor in the mix.

 The startup, Doctronic ...

- **[Tessera Therapeutics to lay off 90 employees, according to document](https://endpoints.news/tessera-therapeutics-to-lay-off-90-employees-according-to-document/)**  
  _Thu, 08 Jan 2026 12:29:39 +0000_  
  Tessera Therapeutics, one of the biggest and most heavily funded gene editing startups, is planning sweeping layoffs that will impact 90 employees just as it begins its first clinical study, according to ...

- **[Vizgen raises $48M for push in spatial biology and multiomics tools](https://endpoints.news/vizgen-raises-48m-for-push-in-spatial-biology-and-multiomics-tools/)**  
  _Thu, 08 Jan 2026 12:00:41 +0000_  
  Vizgen, a startup that has developed techniques to map how genes and proteins are expressed across different cells, has raised a $48 million Series E financing to ramp up production and sales of its tools ...

- **[French biotech Enodia gets ‚Ç¨20.7M aided by Pfizer for protein degrader work](https://endpoints.news/french-biotech-enodia-gets-e20-7m-aided-by-pfizer-for-protein-degrader-work/)**  
  _Thu, 08 Jan 2026 11:30:23 +0000_  
  A tiny French biotech that was formed in February has stapled together about $24 million to see whether it can stop bad proteins at the equivalent of the factory floor, rather than waiting later in ...

- **[Charles Fuchs leaves Roche to steer ADC pipeline at Tubulis shortly after $401M Series C](https://endpoints.news/charles-fuchs-leaves-roche-to-steer-adc-pipeline-at-tubulis-shortly-after-401m-series-c/)**  
  _Thu, 08 Jan 2026 11:30:10 +0000_  
  Charles Fuchs, a well-known figure in oncology drug R&D, has left one of the largest cancer drugmakers to be the chief medical officer of a German biotech startup that's attempting to become a leading independent ...

- **[Lilly to pay $1.2B for Ventyx and its NLRP3 drugs](https://endpoints.news/lilly-to-pay-1-2b-for-ventyx-and-its-nlrp3-drugs/)**  
  _Wed, 07 Jan 2026 21:29:45 +0000_  
  Eli Lilly has made a nearly $1.2 billion deal for Ventyx Biosciences, which has multiple drugs in the clinic for autoimmune, cardiovascular and neurological conditions, the companies announced Wednesday.

 The Indianapolis drugmaker

- **[Immuneering‚Äôs pancreatic cancer pill continues to beat standard care, updated first-line data show](https://endpoints.news/immuneerings-pancreatic-cancer-pill-continues-to-beat-standard-care-updated-first-line-data-show/)**  
  _Wed, 07 Jan 2026 21:00:19 +0000_  
  Immuneering‚Äôs oral pancreatic cancer therapy demonstrated an overall survival rate of 64% at one year when used as the initial treatment, the company said Wednesday.

 This is notably better than standard of care, and Immuneering ...

- **[FDA in 2025 holds fewest number of adcomms since the pandemic](https://endpoints.news/fda-in-2025-holds-fewest-number-of-adcomms-since-the-pandemic/)**  
  _Wed, 07 Jan 2026 18:28:09 +0000_  
  Dwindling FDA advisory committee meetings in 2025 set the stage for fewer opportunities for the agency to discuss difficult regulatory questions with outside experts, potentially leading to more questionable approvals.

 The FDA in 2025 held ...

- **[BridgeBio shares KRAS data; Hutchmed's Phase 3 success in China](https://endpoints.news/bridgebio-shares-kras-data-hutchmeds-phase-3-success-in-china/)**  
  _Wed, 07 Jan 2026 15:26:03 +0000_  
  Plus, news about Monte Rosa, Denali, Aktis and offerings from Praxis and Crinetics.

 ü´Å BridgeBio‚Äôs cancer spinout divulges early KRAS data: BridgeBio Oncology Therapeutics said that its ...

- **[GSK, Ionis say they may have a cure for some hepatitis B patients after Phase 3 win](https://endpoints.news/gsk-ionis-say-they-may-have-a-cure-for-some-hepatitis-b-patients-after-phase-3-win/)**  
  _Wed, 07 Jan 2026 14:42:45 +0000_  
  GSK and Ionis Pharmaceuticals on Wednesday said their antisense therapy for hepatitis B has succeeded in its two registrational trials.

 Although few details were released, it is possible their approach could amount to a cure ...


## Fierce Biotech

- **[<a href="https://www.fiercebiotech.com/biotech/lilly-buys-inflammation-biotech-venytx-12b-wake-parkinsons-cardiovascular-readouts" hreflang="en">Lilly buys inflammation biotech Venytx for $1.2B in wake of Parkinson's, CV readouts</a>](https://www.fiercebiotech.com/biotech/lilly-buys-inflammation-biotech-venytx-12b-wake-parkinsons-cardiovascular-readouts)**  
  _Jan 8, 2026 5:04am_  
  Ventyx has achieved its goal of securing Big Pharma commitment to its pipeline, with Eli Lilly swooping in to buy the inflammation biotech outright for $1.2 billion.

- **[<a href="https://www.fiercebiotech.com/biotech/build-future-pharmas-must-embrace-ai-patient-experience-and-new-rd-frontiers-pwc" hreflang="en">Innovation isn't enough: Biopharma needs urgent reinvention, PwC says</a>](https://www.fiercebiotech.com/biotech/build-future-pharmas-must-embrace-ai-patient-experience-and-new-rd-frontiers-pwc)**  
  _Jan 7, 2026 3:50pm_  
  Attempting to scry the future of the pharmaceutical industry, professional services juggernaut PwC has laid out lofty ambitions for what it believes drugmakers could achieve by 2035‚Äîas well as the steps those companies should take in 2026 to start getting ahead.

- **[<a href="https://www.fiercebiotech.com/biotech/lilly-links-indupro-next-gen-cancer-treatment-deal-worth-950m" hreflang="en">Lilly links up with InduPro in next-gen cancer treatment deal worth up to $950M</a>](https://www.fiercebiotech.com/biotech/lilly-links-indupro-next-gen-cancer-treatment-deal-worth-950m)**  
  _Jan 7, 2026 3:32pm_  
  Shortly after securing a partnership with Sanofi, InduPro is linking up with Eli Lilly in efforts to discover new cancer treatments via a pact that could be worth up to $950 million.

- **[<a href="https://www.fiercebiotech.com/cro/wep-clinical-grabs-european-cro-siron-clinical-broadening-global-capabilities" hreflang="en">WEP Clinical grabs European CRO Siron Clinical, broadening global capabilities</a>](https://www.fiercebiotech.com/cro/wep-clinical-grabs-european-cro-siron-clinical-broadening-global-capabilities)**  
  _Jan 7, 2026 2:28pm_  
  With the acquisition, North Carolina-based WEP Clinical can integrate Siron Clinical's expertise in complex disease areas in its clinical trials division.

- **[<a href="https://www.fiercebiotech.com/research/gilead-study-finds-hiv-can-evolve-resist-lenacapavir-doing-so-hampers-virus-replication" hreflang="en">Gilead study finds HIV can evolve to resist lenacapavir, but doing so hampers the virus' replication</a>](https://www.fiercebiotech.com/research/gilead-study-finds-hiv-can-evolve-resist-lenacapavir-doing-so-hampers-virus-replication)**  
  _Jan 7, 2026 12:43pm_  
  Though Gilead Sciences made waves last June with a landmark FDA approval for its twice-yearly HIV preventive Yeztugo (lenacapavir), the first-in-class drug had previously been used as a long-acting treatment for the viral infection. Now, Gilead has conducted an analysis of a phenomenon that can undermine all infectiou‚Ä¶

- **[<a href="https://www.fiercebiotech.com/biotech/pulmocide-calls-curtains-phase-3-antifungal-trial-after-low-response-and-patient-deaths" hreflang="en">Pulmocide calls curtains on phase 3 antifungal trial over low response, higher mortality rate</a>](https://www.fiercebiotech.com/biotech/pulmocide-calls-curtains-phase-3-antifungal-trial-after-low-response-and-patient-deaths)**  
  _Jan 7, 2026 11:00am_  
  The show is over for Pulmocide‚Äôs phase 3 trial after patients given its investigational inhaled antifungal had lower response rates and a higher chance of death than patients in the control arm.

- **[<a href="https://www.fiercebiotech.com/biotech/amgen-dances-disco-618m-cancer-target-pact" hreflang="en">Amgen dances with Disco in $618M cancer target pact</a>](https://www.fiercebiotech.com/biotech/amgen-dances-disco-618m-cancer-target-pact)**  
  _Jan 7, 2026 9:31am_  
  Amgen is getting down with Disco Pharmaceuticals, commissioning the German outfit to work on cancer therapies focused on a target the biotech has already identified.

- **[<a href="https://www.fiercebiotech.com/biotech/rakuten-lights-path-2028-fda-filing-fresh-100m-raise" hreflang="en">Rakuten lights path to 2028 FDA filing with fresh $100M raise</a>](https://www.fiercebiotech.com/biotech/rakuten-lights-path-2028-fda-filing-fresh-100m-raise)**  
  _Jan 7, 2026 9:20am_  
  Rakuten Medical has added to its tally of megarounds, pocketing another $100 million to push its lead light-based cancer therapy toward a targeted FDA approval filing in 2028.

- **[<a href="https://www.fiercebiotech.com/medtech/staar-surgicals-takeover-saga-ends-shareholder-revolt-stops-alcons-attempted-merger-deal" hreflang="en">Staar Surgical's takeover saga ends as shareholder revolt stops Alcon's attempted merger deal</a>](https://www.fiercebiotech.com/medtech/staar-surgicals-takeover-saga-ends-shareholder-revolt-stops-alcons-attempted-merger-deal)**  
  _Jan 7, 2026 2:20am_  
  Staar Surgical will remain independent after a bitter shareholder battle that has raged for the past several months has now ended the attempted buyout of the company by Alcon.


## MHRA ‚Äì News

- **[Improving Information Supplied with Gabapentinoids (Pregabalin/Gabapentin), Benzodiazepines and Z-Drugs](https://www.gov.uk/drug-safety-update/improving-information-supplied-with-gabapentinoids-pregabalin-slash-gabapentin-benzodiazepines-and-z-drugs)**  
  _2026-01-08T11:01:39Z_  
  The MHRA has reviewed the warnings regarding addiction, dependence, withdrawal, and
tolerance for gabapentin, pregabalin, benzodiazepines, and z-drugs. The findings (detailed in the Public Assessment Report) were that it was necessary to strengthen these warnings in the product information and on packaging to better i‚Ä¶


## arXiv q-bio

- **[MixRx: Predicting Drug Combination Interactions with LLMs](https://arxiv.org/abs/2601.03277)**  
  _Thu, 08 Jan 2026 00:00:00 -0500_  
  arXiv:2601.03277v1 Announce Type: new 
Abstract: MixRx uses Large Language Models (LLMs) to classify drug combination interactions as Additive, Synergistic, or Antagonistic, given a multi-drug patient history. We evaluate the performance of 4 models, GPT-2, Mistral Instruct 2.0, and the fine-tuned counterparts. Our re‚Ä¶

- **[MetagenBERT: a Transformer-based Architecture using Foundational genomic Large Language Models for novel Metagenome Representation](https://arxiv.org/abs/2601.03295)**  
  _Thu, 08 Jan 2026 00:00:00 -0500_  
  arXiv:2601.03295v1 Announce Type: new 
Abstract: Metagenomic disease prediction commonly relies on species abundance tables derived from large, incomplete reference catalogs, constraining resolution and discarding valuable information contained in DNA reads. To overcome these limitations, we introduce MetagenBERT, a T‚Ä¶

- **[Understanding the temperature response of biological systems: Part II -- Network-level mechanisms and emergent dynamics](https://arxiv.org/abs/2601.03307)**  
  _Thu, 08 Jan 2026 00:00:00 -0500_  
  arXiv:2601.03307v1 Announce Type: new 
Abstract: Building on the phenomenological and microscopic models reviewed in Part I, this second part focuses on network-level mechanisms that generate emergent temperature response curves. We review deterministic models in which temperature modulates the kinetics of coupled bio‚Ä¶

- **[A Comprehensive Database of Leaf Temperature, Water, and CO 2 Fluxes in Young Oil Palm Plants Across Diverse Climate Scenarios](https://arxiv.org/abs/2601.03308)**  
  _Thu, 08 Jan 2026 00:00:00 -0500_  
  arXiv:2601.03308v1 Announce Type: new 
Abstract: Functional-structural plant models (FSPM) replicate plants' responses to their environment and are useful for predicting behavior in a changing climate. However, they rely on detailed measurements of traits, which are difficult to collect consistently across scales, oft‚Ä¶

- **[Emergent togetherness in collaborative dance improvisation: neural and motor synchronization reveal a coupling-decoupling paradox](https://arxiv.org/abs/2601.03478)**  
  _Thu, 08 Jan 2026 00:00:00 -0500_  
  arXiv:2601.03478v1 Announce Type: new 
Abstract: Collective improvisation in dance provides a rich natural laboratory for studying emergent coordination in coupled neuro-motor systems. Here, we investigate how training shapes spontaneous synchronization patterns in both movement and brain signals during collaborative‚Ä¶

- **[A Quantifiable Information-Processing Hierarchy Provides a Necessary Condition for Detecting Agency](https://arxiv.org/abs/2601.03498)**  
  _Thu, 08 Jan 2026 00:00:00 -0500_  
  arXiv:2601.03498v1 Announce Type: new 
Abstract: As intelligent systems are developed across diverse substrates - from machine learning models and neuromorphic hardware to in vitro neural cultures - understanding what gives a system agency has become increasingly important. Existing definitions, however, tend to rely‚Ä¶

- **[Integrated strong reciprocity enables productive punishment and protective defection](https://arxiv.org/abs/2601.03681)**  
  _Thu, 08 Jan 2026 00:00:00 -0500_  
  arXiv:2601.03681v1 Announce Type: new 
Abstract: Cooperation in large groups and one-shot interactions is often hindered by freeloading. Punishment can enforce cooperation, but it is usually regarded as wasteful because the costs of punishing offset its benefits. Here, we analyze an evolutionary game model that integr‚Ä¶

- **[Data-driven inference of brain dynamical states from the r-spectrum of correlation matrices](https://arxiv.org/abs/2601.03796)**  
  _Thu, 08 Jan 2026 00:00:00 -0500_  
  arXiv:2601.03796v1 Announce Type: new 
Abstract: We present a data-driven framework to characterize large-scale brain dynamical states directly from correlation matrices at the single-subject level. By treating correlation thresholding as a percolation-like probe of connectivity, the approach tracks multiple cluster-‚Ä¶

- **[Bayes-PD: Exploring a Sequence to Binding Bayesian Neural Network model trained on Phage Display data](https://arxiv.org/abs/2601.03930)**  
  _Thu, 08 Jan 2026 00:00:00 -0500_  
  arXiv:2601.03930v1 Announce Type: new 
Abstract: Phage display is a powerful laboratory technique used to study the interactions between proteins and other molecules, whether other proteins, peptides, DNA or RNA. The under-utilisation of this data in conjunction with deep learning models for protein design may be attr‚Ä¶

- **[Restoring information in aged gene regulatory networks by single knock-ins](https://arxiv.org/abs/2601.04016)**  
  _Thu, 08 Jan 2026 00:00:00 -0500_  
  arXiv:2601.04016v1 Announce Type: new 
Abstract: A hallmark of aging is loss of information in gene regulatory networks. These networks are tightly connected, raising the question of whether information could be restored by perturbing single genes. We develop a simple theoretical framework for information transmission‚Ä¶

- **[Stigmergic optimal transport](https://arxiv.org/abs/2601.04111)**  
  _Thu, 08 Jan 2026 00:00:00 -0500_  
  arXiv:2601.04111v1 Announce Type: new 
Abstract: Efficient navigation in swarms often relies on the emergence of decentralized approaches that minimize traversal time or energy. Stigmergy, where agents modify a shared environment that then modifies their behavior, is a classic mechanism that can encode this strategy.‚Ä¶

- **[Tool Choice Matters: Evaluating edgeR vs. DESeq2 for Sensitivity, Robustness, and Cross-Study Performance](https://arxiv.org/abs/2601.04122)**  
  _Thu, 08 Jan 2026 00:00:00 -0500_  
  arXiv:2601.04122v1 Announce Type: new 
Abstract: Differential gene expression (DGE) analysis is foundational to transcriptomic research, yet tool selection can substantially influence results. This study presents a comprehensive comparison of two widely used DGE tools, edgeR and DESeq2, using real and semi-simulated b‚Ä¶

- **[Progressive Bayesian Confidence Architectures for Cold-Start Personal Health Analytics: Formalizing Early Insight Through Posterior Contraction and Risk-Aware Interpretation](https://arxiv.org/abs/2601.03299)**  
  _Thu, 08 Jan 2026 00:00:00 -0500_  
  arXiv:2601.03299v1 Announce Type: cross 
Abstract: Personal health analytics systems face a persistent cold-start dilemma: users expect meaningful insights early in data collection, while conventional statistical inference requires data volumes that often exceed engagement horizons. Existing approaches either delay in‚Ä¶

- **[Investigating Knowledge Distillation Through Neural Networks for Protein Binding Affinity Prediction](https://arxiv.org/abs/2601.03704)**  
  _Thu, 08 Jan 2026 00:00:00 -0500_  
  arXiv:2601.03704v1 Announce Type: cross 
Abstract: The trade-off between predictive accuracy and data availability makes it difficult to predict protein--protein binding affinity accurately. The lack of experimentally resolved protein structures limits the performance of structure-based machine learning models, which‚Ä¶

- **[Minimal branching and fusion morphogenesis approaches biological multi-objective optimality](https://arxiv.org/abs/2601.03877)**  
  _Thu, 08 Jan 2026 00:00:00 -0500_  
  arXiv:2601.03877v1 Announce Type: cross 
Abstract: Many biological networks grow by elongation of filaments that can branch and fuse -- typical examples include fungal mycelium or slime mold. These networks must simultaneously perform multiple tasks such as transport, exploration, and robustness under finite resources‚Ä¶

- **[Assessment of scoring functions for computational models of protein-protein interfaces](https://arxiv.org/abs/2407.16580)**  
  _Thu, 08 Jan 2026 00:00:00 -0500_  
  arXiv:2407.16580v2 Announce Type: replace 
Abstract: A goal of computational studies of protein-protein interfaces (PPIs) is to predict the binding site between two monomers that form a heterodimer. The simplest version of this problem is to rigidly re-dock the bound forms of the monomers, which involves generating co‚Ä¶

- **[Brain-Inspired Exploration of Functional Networks and Key Neurons in Large Language Models](https://arxiv.org/abs/2502.20408)**  
  _Thu, 08 Jan 2026 00:00:00 -0500_  
  arXiv:2502.20408v2 Announce Type: replace 
Abstract: In recent years, the rapid advancement of large language models (LLMs) in natural language processing has sparked significant interest among researchers to understand their mechanisms and functional characteristics. Although prior studies have attempted to explain L‚Ä¶

- **[Functional classification of metabolic networks](https://arxiv.org/abs/2503.14437)**  
  _Thu, 08 Jan 2026 00:00:00 -0500_  
  arXiv:2503.14437v3 Announce Type: replace 
Abstract: Chemical reaction networks underpin biological and physical phenomena across scales, from microbial interactions to planetary atmosphere dynamics. Bacterial communities exhibit complex competitive interactions for resources, human organs and tissues demonstrate spec‚Ä¶

- **[The mechanics of the $\textit{Less In More Out}$ artificial heart: modeling fabric-based soft robotic devices](https://arxiv.org/abs/2510.14984)**  
  _Thu, 08 Jan 2026 00:00:00 -0500_  
  arXiv:2510.14984v2 Announce Type: replace 
Abstract: Recently, the Less In More Out device, a fluidically actuated soft total artificial heart was proposed. This device uses arrays of pouch motors to achieve a positive fluidic lever when pneumatically actuated against physiological hemodynamic conditions. Extensive ex‚Ä¶

- **[Inference in conditioned dynamics through causality restoration](https://arxiv.org/abs/2210.10179)**  
  _Thu, 08 Jan 2026 00:00:00 -0500_  
  arXiv:2210.10179v3 Announce Type: replace-cross 
Abstract: Computing observables from conditioned dynamics is typically computationally hard, because, although obtaining independent samples efficiently from the unconditioned dynamics is usually feasible, generally most of the samples must be discarded (in a form of im‚Ä¶

- **[SPD Matrix Learning for Neuroimaging Analysis: Perspectives, Methods, and Challenges](https://arxiv.org/abs/2504.18882)**  
  _Thu, 08 Jan 2026 00:00:00 -0500_  
  arXiv:2504.18882v2 Announce Type: replace-cross 
Abstract: Neuroimaging provides essential tools for characterizing brain activity by quantifying connectivity strength between remote regions, using different modalities that capture different aspects of connectivity. Yet, decoding meaningful neural signatures must cont‚Ä¶
